[go: up one dir, main page]

EP0460084A1 - Nouveaux beta-methoxyacrylates, leur production et leur utilisation - Google Patents

Nouveaux beta-methoxyacrylates, leur production et leur utilisation

Info

Publication number
EP0460084A1
EP0460084A1 EP90904345A EP90904345A EP0460084A1 EP 0460084 A1 EP0460084 A1 EP 0460084A1 EP 90904345 A EP90904345 A EP 90904345A EP 90904345 A EP90904345 A EP 90904345A EP 0460084 A1 EP0460084 A1 EP 0460084A1
Authority
EP
European Patent Office
Prior art keywords
formula
compounds
methoxyacrylates
cells
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90904345A
Other languages
German (de)
English (en)
Inventor
Lothar Daum
Gerhard Keilhauer
Hubert Sauter
Gunda Bertram
Timm Anke
Wolfgang Weber
Wolfgang Steglich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of EP0460084A1 publication Critical patent/EP0460084A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Definitions

  • the present invention relates to new ⁇ -methoxyacrylates, processes for their preparation and their use in combating
  • R 1 represents hydrogen or an optionally unsaturated hydrocarbon radical having up to 10 carbon atoms, which is represented by fluorine, chlorine, bromine, C 1-6 alkoxy, C 2-6 alkenoxy or C 2-6 alkynoxy or by an optionally fluorine, Chlorine, bromine, iodine, trifluoromethyl, C 1-4 -alkyl or C 1-4 -alkoxy substituted phenyl or phenoxy may be substituted,
  • R 2 and R 3 are the same or different and are hydrogen atoms
  • R 2 and R 3 together represent a C 2-8 alkylene group, have a better effect
  • the compounds of formula I have two centers of chirality in
  • the configuration isomers can expediently also be separated at the stage of intermediates of the formula II (see below). A separation of the configuration isomers is not necessary for the use of the compounds according to the invention.
  • the ⁇ -methoxyacrylate group can be in the E or Z configuration.
  • the compounds of formula I are preferred with
  • R 4 is a C 1-8 alkyl radical, reacted in the presence of a base and the compounds thus obtained - if R 1 is an unsaturated radical - optionally hydrogenated.
  • the reaction of the compounds II with III takes place in the sense of a Wittig-Homer reaction in the presence of a solvent and a base, such as lithium diisopropylamide, phenyllithium, butyllithium, sodium alcoholate, sodium amide, sodium hydride or potassium t-butoxide.
  • a solvent and a base such as lithium diisopropylamide, phenyllithium, butyllithium, sodium alcoholate, sodium amide, sodium hydride or potassium t-butoxide.
  • Suitable solvents for the reaction are benzene, dimethylformamide, tetrahydrofuran, diethyl ether and dimethoxyethane.
  • the reaction is useful in a
  • Sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, 1,8-diazabicyclo [5,4,0] undec-7-ene, diisopropylmethylamine and diisopropylethylamine are particularly suitable as auxiliary bases for the reaction V ⁇ VI.
  • Preferred solvents are dimethylformamide, tetrahydrofuran, diethyl ether, methanol, ethanol, acetonitrile and acetone.
  • the reaction V ⁇ VI works well at temperatures between 0 and 30 ° C.
  • reaction mixture was diluted with diethyl ether and washed 1x with semi-saturated NaCl solution to remove the catalyst. After drying over MgSO 4, the ether phase was concentrated in vacuo.
  • reaction mixture was poured into semi-saturated NaCl solution, extracted with ether and dried over MgSO 4 .
  • the two diasteromers were formed in a ratio of about 1: 1.
  • Diastereomer 1 330 mg of colorless crystals
  • Diastereomer 2 308 mg colorless crystals
  • Diastereomer 1 (C 17 H 20 O 5 ) (MW 304):
  • Diastereomer 2 (C 17 H 20 O 5 ) (MW 304): 1 H-NMR (200 MHz, benzene-d 6 ):
  • the mixture was allowed to warm to room temperature and stirred for 24 h.
  • the reaction solution was poured into 15 ml of ether, washed twice with 3 ml of water and once with 3 ml of saturated NaCl solution. After drying over MgSO 4 , the mixture was evaporated.
  • the raw product was with
  • Diastereomer 1 (C 29 H 32 O 7 , MW 492):
  • Diastereomer 1 (C 32 H 36 O 7 , MW 532):
  • Distereomer 2 (C 32 H 36 O 7 , MW 532):
  • the new compounds in particular the compounds of Examples 1 to 16 - show good antiviral, antiproliferative and cytotoxic activity.
  • the following examples explain the effects of the new substances:
  • the oxygen consumption was measured polarographically in an airtight container (3 ml volume, with magnetic stirrer) with an oxygen electrode.
  • the test mushroom was grown from a spore suspension to a mycelium weight of 10-20 mg mycelium wet weight / ml. The measurements were carried out with a mycelium concentration of 25-30 mg mycelium wet weight / ml in 1% glucose solution. After a short constant course of breathing, the compounds (0.3 mg / ml) dissolved in methanol were added to the suspension and the 02 consumption was recorded. The experiment was carried out using strobilurin A as a comparative compound. The results of the percent breathing inhibition are shown in Table 1. Table 1
  • HeLa-S3 cells were on a 96-well titer plate with a cell density of 4 x 105 cells / ml in medium F12 with 10% fetal calf serum
  • the cells were spread out on the surface and the medium was changed.
  • the cells were incubated with the medium containing the test compounds (10, 1, 0.1 or 0.01 ⁇ g per ml medium) for 72 h (37 ° C., 5% CO 2 ). After 72 hours, the normally epithelial-like growing cells were fibroblast-like
  • Morphology From a 45% growth inhibition, the change in morphology is significantly visible through the action of the substances.
  • the experiment was carried out using strobilurin A as a comparative compound.
  • the cell density was measured by determining the total protein content per hole.
  • the values given show the results after three days of incubation with the test substances and are listed in Table 2 as a percentage of the total protein of the untreated control.
  • Antiviral effect in HEp-2 cells on VSV The determination of the antiviral activity of a test compound is based on the measurement of the protection of human HEp-2 cells as indicator cells against the cytopathic effect (CPE) of Vesicular Stomatitis Virus (VSV).
  • CPE cytopathic effect
  • the percentage of protected cells in the cultures treated with the test compounds and subsequently infected with VSV was determined by means of crystal violet staining / the measure of the antiviral activity based on 0 and 100% protection was determined as the sample concentration, which leads to 50% protection.
  • Table 3 lists the test substances with the concentration which 50% protects the HEp-2 cells against the cytopathic effect of VSV.
  • Example 1 In contrast to rHuIFN- ⁇ , the substance of Example 1 also showed an antiproliferative effect under these test conditions compared to cell control. The antiviral and antiproliferative activities The substances of Example 1 ran in parallel and correlated with a morphological change in the cells, ie the cells were elongated compared to the cell control and had neurite-like processes.
  • Example D The substances of Example 1 ran in parallel and correlated with a morphological change in the cells, ie the cells were elongated compared to the cell control and had neurite-like processes.
  • tumor cells of different tissue origin 5637-6: human bladder carcinoma; HT-29: human colon carcinoma; B-16: murine melanoma
  • 1 to 2 ⁇ 103 exponential growth tumor cells were plated in 96-well plates in complete growth medium (RPMI 1640 x 10% fetal calf serum) and incubated overnight under standard culture conditions (37 ° C, 5% carbon dioxide, water vapor-saturated atmosphere). The substance was added the next day, serial titrations of substances 1 B1 and 1 B2 being carried out over a concentration range of 10 -4 to 10 -9 M. After a further incubation of 72 h under standard conditions, the cell number was determined by staining with crystal violet and a subsequent photometric

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Des beta-méthoxyacrylates ayant la formule (I), dans laquelle R1, R2 et R3 ont la signification donnée dans la description, sont utiles pour traiter des maladies. L'invention concerne également leur production.
EP90904345A 1989-02-25 1990-02-20 Nouveaux beta-methoxyacrylates, leur production et leur utilisation Withdrawn EP0460084A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3905911A DE3905911A1 (de) 1989-02-25 1989-02-25 Neue ss-methoxyacrylate, ihre herstellung und verwendung
DE3905911 1989-02-25

Publications (1)

Publication Number Publication Date
EP0460084A1 true EP0460084A1 (fr) 1991-12-11

Family

ID=6374929

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90904345A Withdrawn EP0460084A1 (fr) 1989-02-25 1990-02-20 Nouveaux beta-methoxyacrylates, leur production et leur utilisation

Country Status (5)

Country Link
EP (1) EP0460084A1 (fr)
JP (1) JPH04503671A (fr)
CA (1) CA2047195A1 (fr)
DE (1) DE3905911A1 (fr)
WO (1) WO1990010006A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4443648C2 (de) * 1994-12-08 1999-01-21 Akzo Nobel Nv Verfahren zur Herstellung von Polyestern und Copolyestern
EP2001555A1 (fr) * 2006-03-29 2008-12-17 Basf Se Utilisation de strobilurine pour le traitement de troubles du metabolisme du fer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815484A1 (de) * 1988-05-06 1989-11-16 Basf Ag Neue strobilurinderivate, ihre herstellung und verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9010006A2 *

Also Published As

Publication number Publication date
DE3905911A1 (de) 1990-08-30
CA2047195A1 (fr) 1990-08-26
WO1990010006A2 (fr) 1990-09-07
WO1990010006A3 (fr) 1990-11-01
JPH04503671A (ja) 1992-07-02

Similar Documents

Publication Publication Date Title
EP1001951B1 (fr) Derives de thiazole, leur procede de production et leur utilisation
EP0603649A1 (fr) 4-Phenylpyridones et 4-phenyl-2-alkoxypyridines substituées comme inhibiteurs de réductase de HMG-CoA
EP0496238A1 (fr) Benzoxazépines et benzothiazépines substituées, procédé pour leur préparation et leur application comme medicaments
CH633250A5 (de) Verfahren zur herstellung von neuen polyprenylderivaten.
EP0716082A1 (fr) Oxy-phényl-(phényl)glycinolamides substitués avec un hétérocycle ayant une activité antiathérosclérotique
DE69823844T2 (de) Verfahren zur herstellung von als protease inhibitoren wervollen 4-hydroxy-2-oxo-pyran-derivaten
CH646147A5 (de) 4,5-ungesaettigte prostansaeurederivate.
DE2609017A1 (de) Basische oximaether, solche enthaltende arzneimittel und verfahren zur herstellung derselben
DE2225190C3 (de) Neue Acetophenonoximderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
EP0460084A1 (fr) Nouveaux beta-methoxyacrylates, leur production et leur utilisation
DE3302814C2 (fr)
EP0300249B1 (fr) Acides [1H-pyrrolyl-3]-7 dihydroxy-3,5 heptanoiques, delta-lactones et sels correspondants, procédés pour leur préparation , leur application comme médicaments, compositions pharmaceutiques et produits intermédiaires
EP0110219B1 (fr) Nitriles hétérocycliques substitués, leur procédé de préparation et leur application comme médicaments
DE3751896T2 (de) Acridinone als chromogene Enzymsubstrate
DE2759994C2 (de) Ketale von 4-(1-Hydroxy-1-methylethyl)-3-cyclohexen-1-on und Verfahren zu ihrer Herstellung
DE69500294T2 (de) Benzoheterocyclische Verbindungen als Antioxidantien
DE69326321T2 (de) Neues aminosäurederivat
DE2509797C2 (de) Phthalimidine, deren physiologisch verträgliche Säureadditionssalze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2264903C3 (de) Piperidinderivate und ihre Herstellung
DE3200747A1 (de) N-(4-silaalkylen- bzw. alkenylen-but-4-in-2-en-l-yl)methanamin-derivate als chemotherapeutische mittel
EP0818447B1 (fr) 6-(Hydroxyméthyl-éthyl)pyridines comme inhibiteurs de HMG-CoA réductase
DE2810923A1 (de) Neue zyklische phosphorsaeureamidester, verfahren zu ihrer herstellung sowie diese ester enthaltende insektizide
DE60214412T2 (de) Simplifizierte sarcodictyn-derivate als anti-tumor-mittel
DE2923697A1 (de) Neue 1-pyrrol- und pyrrolidin-carbonsaeure-derivate und verfahren zu deren herstellung
DE3818570A1 (de) Neue 6-substituierte-4-hydroxy-tetrahydro-pyran -2-on-derivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910730

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19930120